Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone

This article was originally published in The Pink Sheet Daily

Executive Summary

WuXi expects to have a full service toxicology operation in China in the next five years, which would have been accelerated by a merger with Charles River. By 2015, China is expected to gain more of the global toxicology service market projected to reach $150 million to $200 million.

You may also be interested in...

Charles River Abandons WuXi PharmaTech Just Days Before Crucial Shareholder Votes On Planned Merger

BEIJING - Like a prospective bride who has been jilted at the very last moment by a suitor, Shanghai's WuXi PharmaTech has been abandoned by the Massachusetts-headquartered Charles River Laboratories on the eve of the two contract research organizations' merger

China Anticipates Speeding Up R&D By Joining OECD As Observer - DIA China Conference

BEIJING - China's status as an observer country in the Organization for Economic Cooperation and Development will help the local contract research organization sector get faster access to the world's top biomedical markets for drugs developed and tested in China, said leaders at DIA's China conference May 19

China's Wuxi PharmaTech Signs New Agreement On Toxicology Studies Training And Services With J&J Unit

BEIJING - Just days after disclosing that a newly launched drug safety testing center had been accredited by a U.S. group, leading Chinese contract research organization Wuxi PharmaTech signed a toxicology deal with Johnson & Johnson Pharmaceutical Research & Development

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts